TAK Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥13.86 |
| 52 Week High | JP¥15.08 |
| 52 Week Low | JP¥12.58 |
| Beta | 0.46 |
| 11 Month Change | -0.72% |
| 3 Month Change | -7.10% |
| 1 Year Change | -1.70% |
| 33 Year Change | 1.76% |
| 5 Year Change | -30.87% |
| Change since IPO | -34.78% |
Recent News & Updates
Recent updates
Takeda Pharmaceuticals: An Interesting Option For Income Investors
Oct 07Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
Jun 06Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits
Mar 03Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
Oct 24Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
Aug 31Takeda: Upside Case Strengthening, Looking To 15x Earnings
Jun 21Shareholder Returns
| TAK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.7% | 1.9% | 0.7% |
| 1Y | -1.7% | 12.1% | 32.2% |
Return vs Industry: TAK underperformed the US Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: TAK underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| TAK volatility | |
|---|---|
| TAK Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TAK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TAK's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 49,281 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| TAK fundamental statistics | |
|---|---|
| Market cap | US$43.67b |
| Earnings (TTM) | US$1.94b |
| Revenue (TTM) | US$30.40b |
22.5x
P/E Ratio1.4x
P/S RatioIs TAK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAK income statement (TTM) | |
|---|---|
| Revenue | JP¥4.55t |
| Cost of Revenue | JP¥1.55t |
| Gross Profit | JP¥3.00t |
| Other Expenses | JP¥2.71t |
| Earnings | JP¥290.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 182.94 |
| Gross Margin | 65.95% |
| Net Profit Margin | 6.38% |
| Debt/Equity Ratio | 73.0% |
How did TAK perform over the long term?
See historical performance and comparison